| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | ADK |
| Uniprot No | P55263 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 22-362aa |
| 氨基酸序列 | MGSSHHHHHHSSGLVPRGSHMRENILFGMGNPLLDISAVVDKDFLDKYSL KPNDQILAEDKHKELFDELVKKFKVEYHAGGSTQNSIKVAQWMIQQPHKA ATFFGCIGIDKFGEILKRKAAEAHVDAHYYEQNEQPTGTCAACITGDNRS LIANLAAANCYKKEKHLDLEKNWMLVEKARVCYIAGFFLTVSPESVLKVA HHASENNRIFTLNLSAPFISQFYKESLMKVMPYVDILFGNETEAATFARE QGFETKDIKEIAKKTQALPKMNSKRQRIVIFTQGRDDTIMATESEVTAFA VLDQDQKEIIDTNGAGDAFVGGFLSQLVSDKPLTECIRAGHYAASIIIRR TGCTFPEKPDFH |
| 预测分子量 | 41 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于ADK(腺苷激酶)重组蛋白的3篇文献示例(虚构内容，仅供参考格式)：
1. **文献名称**：*Expression and Purification of Recombinant Human Adenylate Kinase in E. coli*
**作者**：Zhang L. et al.
**摘要**：本研究报道了通过大肠杆菌表达系统高效表达人源ADK重组蛋白的优化方法，利用His标签纯化技术获得高纯度蛋白，并验证其酶活性，为后续结构研究奠定基础。
2. **文献名称**：*Structural Insights into ADK1 Dynamics by X-ray Crystallography*
**作者**：Smith J.R., Tanaka M.
**摘要**：通过X射线晶体学解析了重组ADK1的构象变化，揭示了其在ATP/AMP结合过程中的动态结构特征，阐明了催化机制的关键残基。
3. **文献名称**：*ADK Recombinant Protein Attenuates Neuroinflammation in Parkinson's Disease Models*
**作者**：Chen X. et al.
**摘要**：研究证明，外源性重组ADK蛋白可通过调节细胞外腺苷水平，抑制小胶质细胞过度活化，显著改善帕金森病模型中的神经炎症反应。
(注：以上文献为示例，实际引用需查询真实数据库如PubMed或Web of Science。)
**Background of ADK Recombinant Protein**
Adenylate kinase (ADK) is a conserved phosphotransferase enzyme critical for cellular energy homeostasis. It catalyzes the reversible transfer of a phosphate group between adenosine nucleotides (e.g., ATP + AMP ↔ 2 ADP), playing a vital role in maintaining nucleotide balance, energy metabolism, and intracellular signaling. ADK exists in multiple isoforms across tissues, with cytosolic (ADK1) and mitochondrial (ADK2) forms regulating distinct metabolic pathways. Dysregulation of ADK activity is linked to metabolic disorders, neurological diseases, and cancer, making it a target for therapeutic research.
Recombinant ADK proteins are engineered using molecular cloning techniques, where the ADK gene is expressed in heterologous systems like *E. coli*, yeast, or mammalian cells. This approach ensures high purity, scalability, and consistency for research and industrial applications. Recombinant ADK retains native enzymatic activity and structural integrity, enabling studies on its kinetic properties, substrate specificity, and interactions with inhibitors or modulators.
In biomedical research, recombinant ADK is utilized to explore nucleotide metabolism dynamics, screen drug candidates targeting energy-related diseases, and develop diagnostic tools. For instance, in neuroscience, ADK’s role in regulating adenosine—a neuromodulator with neuroprotective effects—highlights its relevance in epilepsy and stroke models. Additionally, structural studies using recombinant ADK have advanced the design of small-molecule inhibitors for cancer therapy.
The development of recombinant ADK has significantly accelerated both basic and applied research, offering a reliable tool to dissect its biological functions and therapeutic potential in human health and disease.
×
